SR One
Signal active
Investment Firm
Overview
SR One is the corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately 800 million in more than 180 companies.
Highlights
Founded
1985
Industry
Financial Services
Employees
1-10
Investment
192
Lead Investment
60
Exits
58
Stages
Late Stage Venture, Early Stage Venture, Private Equity, Seed
Investor Type
Venture Capital
Location
United States, North America
Contact Information
Social
Profile Resume
SR One, established in 1985 and headquartered in United States, North America., specializes in Late Stage Venture, Early Stage Venture, Private Equity, Seed investments across Biotechnology, Health Care, Pharmaceutical, Emergency Medicine, Financial Services, Venture Capital, Finance, Information Technology, Life Science, Therapeutics. The organization boasts a portfolio of 190 investments, with an average round size of $49.0M and 58 successful exits. Their recent investments include Melinta Therapeutics, ABS Ventures, MedImmune Ventures, Warburg Pincus, Oxford Bioscience Partners. The highest investment round they participated in was $1017.9B. Among their most notable exits are Melinta Therapeutics and ABS Ventures. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
SR One has made 192 investments. Their most recent investment was on Jul 16, 2024, when Asceneuron raised $100.0M.
SR One has made 46 diversity investments. Their most recent diversity investment was on Mar 06, 2024, when Alumis raised $259.0M.
investments
192
Diversity investments
46
Lead investments
60
Number of exits
58
Investments
192
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| May 07, 2024 | Zenas BioPharma | Health Care | 200.0M |
| Jun 27, 2024 | Kala Pharmaceuticals | Biotechnology | 12.5M |
| Jul 16, 2024 | Asceneuron | Biotechnology | 100.0M |
| Jul 17, 2024 | - | - | 38.0M |
Kala Pharmaceuticals
AsceneuronExits
58
Funding Timeline
Funding rounds
192
Investors
0
Funds
1
Funding Rounds
192
SR One has raised 192 rounds. Their latest funding was raised on Jul 17, 2024 from a Series A - Renalys Pharma round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| May 07, 2024 | Series C - Zenas BioPharma | - | 200.0M | - |
| Jun 27, 2024 | Post-IPO Equity - Kala Pharmaceuticals | - | 12.5M | - |
| Jul 16, 2024 | Series C - Asceneuron | - | 100.0M | - |
| Jul 17, 2024 | Series A - Renalys Pharma | - | 38.0M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.